Application No. 10/511,535 Response dated 02/28/2007

RECEIVED CENTRAL FAX CENTER FEB 2 8 2007

#### Remarks

### Claim Rejection under 35 U.S.C. § 102:

The Examiner has rejected Claims 1-4, 18 and 19 as being anticipated by US 6,569,865 B2.

Applicant respectfully point out that US 6,569,865 B2 discloses and claims a single unsubstituted compound, namely (2'R)-5'-(3-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]. The present invention is directed to substituted compounds, specifically compounds having 1, 2 or 3 substituents as provided in the definition of Ar in Claim 1.

Accordingly, Applicants believe the Examiner is mistaken in making this rejection and respectfully solicits its withdrawal.

RECEIVED CENTRAL FAX CENTER FEB 2 8 2007

Application No. 10/511,535 Response dated 02/28/2007

# Claim Rejection for Double Patenting:

The Examiner has rejected Claims 1-4, 18 and 19 as being not patentably distinct from certain granted patents and copending applications. For clarity, Applicants provide below a Table showing the relationships of Applicants' patents and applications mentioned by the Examiner.

Applicants Docket No.	International Publication No.	US Application No.	US Publication No.	US Patent No.
A1695 (four divisional cases also filed)	WO 99/03859	09/171983		US6110914
A2090 & Div of A2090	WO 00/42044		US2003149065 US2005250802	U\$6995167
100559	None (not filed outside US)	·		US6569865
100332 (international counterpart of 100559)	WO 2002096912	None (not filed in US)		
100694		10/511525		
100695 (this application)		10/511535		

Applicants respectfully request that the rejection for double patenting be held in abeyance until agreement has been reached on the patentability of claims.

FAX NO. 3028868221

Application No. 10/511,535 Response dated 02/28/2007

RECEIVED
CENTRAL FAX CENTER
FEB 2 8 2007

### Statement of Common Ownership

Patents and applications shown in Table 1,

Table 1

Application No.	Publication No.	US Patent No.
PCT/SE98/01364	WO 99/03859	
09/171983		US6110914
09/594703 (Div)	US20020187994	US6369224
10/093939 (Div)	US20030166935	US6703502
10/396215 (Div)	US20050004099	US6706878
10/801085 (Div)	<u>'</u>	Pending
PCT/SE99/02478	WO 00/42044	
09/529654	US2003149065	US6995167
11/181098 (Div)	US2005250802	Pending
	None (not filed	US6569865
	outside US)	
PCT/SE02/01031	WO 2002096912	
(not filed in US)		
PCT/SE03/00615	WO 03/087104	
10/511525	US20050131003	Pending

were, at the time the present invention was made, owned by or subject to an obligation of assignment to AstraZeneca AB.

Application No. 10/511,535 Response dated 02/28/2007 RECEIVED CENTRAL FAX CENTER FEB 2 8 2007

# Claim Rejection under 35 U.S.C. § 103:

The Examiner has rejected Claims 1-4, 18 and 19 as being obvious over certain applications and pending applications as described in the Table above.

Accordingly, because the cited references were at the time the invention was made owned or subject to an obligation of assignment to AstraZeneca, Applicants take the position that the references cannot be cited again the present application and therefore that the rejection is obviated.

Applicants earnestly solicit prompt issuance of a Notice of Allowance.

Respectfully submitted,

Dated: February 28, 2007

Kenneth F. Mitchell Attorney for Applicants Reg. No. 42,007

Telephone: 302/886-7466